In response to the World Health Organization's emphasis on stringent quality control (QC) in antibody production, Creative Biolabs has positioned itself as a key player in the non-GMP antibody production sector. This move caters to the increasing demand for high-quality, research-grade antibodies, offering a flexible alternative to the more costly GMP production processes.
The company's initiative is timely, as research, including studies found on PubMed, highlights the importance of glycosylation in antibody efficacy and safety. A Creative Biolabs scientist noted, 'The surge in research interest and the lack of specialized solutions motivated us to launch our custom antibody production and QC service pipeline.'
Creative Biolabs' services span from process development to aseptic filling, encompassing both upstream and downstream processes tailored to each project's needs. Their OmicsAb™ High-throughput Antibody Production platform enables rapid production of diverse antibody candidates across various hosts, ensuring quality without compromising speed. The scientist added, 'Our QC system ensures purity levels up to 95%, meeting specific requirements like mutation, antibody type, and host selection.'
Moreover, the company excels in producing multispecific antibodies, from bispecifics to more complex constructs, enhancing drug targeting and minimizing off-target effects. Their scFv-Fc fusion platform offers a blend of agility and precision, supported by comprehensive QC measures and technical support.
Beyond its antibody services, Creative Biolabs is fostering future scientific talent through its 2025 Scholarship Program, open to students in biology-related fields. This initiative underscores the company's commitment to advancing science and supporting the next generation of researchers.
